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Trimethoprim–sulfamethoxazole prophylaxis prevents 
severe/life-threatening infections following rituximab 
in antineutrophil cytoplasm antibody-associated 
vasculitis
Andreas Kronbichler,1,2 Julia Kerschbaum,2 Seerapani Gopaluni,1 Joanna tieu,1 
Federico Alberici,1,3 rachel Bronwen Jones,1 rona M Smith,1 david r W Jayne1,4
AbstrACt
Objective We aimed to assess risk factors for the 
development of severe infection in patients with 
antineutrophil cytoplasm antibody-associated vasculitis 
(AAV) receiving rituximab.
Methods 192 patients with AAV were identified. 
Univariate and multivariate analyses were performed 
to identify risk factors for severe infection following 
rituximab. Severe infections were classified as grade ≥3 
as proposed by the Common terminology Criteria for 
Adverse Events V.4.0.
results 95 severe infections were recorded in 49 
(25.52%) patients, corresponding to an event rate of 
26.06 per 100 person-years. the prophylactic use of 
trimethoprim–sulfamethoxazole was associated with a 
lower frequency of severe infections (Hr 0.30, 95% CI 
0.13 to 0.69), while older age (Hr 1.03, 95% CI 1.01 
to 1.05), endobronchial involvement (Hr 2.21, 95% CI 
1.14 to 4.26), presence of chronic obstructive pulmonary 
disease (Hr 6.30, 95% CI 1.08 to 36.75) and previous 
alemtuzumab use (Hr 3.97, 95% CI 1.50 to 10.54) 
increased the risk. When analysis was restricted to 
respiratory tract infections (66.3% of all infections), 
endobronchial involvement (Hr 4.27, 95% CI 1.81 to 
10.06), severe bronchiectasis (Hr 6.14, 95% CI 1.18 to 
31.91), higher neutrophil count (Hr 1.19, 95% CI 1.06 
to 1.33) and major relapse (Hr 3.07, 95% CI 1.30 to 
7.23) as indication for rituximab use conferred a higher 
risk, while refractory disease (Hr 0.25, 95% CI 0.07 
to 0.90) as indication had a lower frequency of severe 
infections.
Conclusions We found severe infections in one quarter 
of patients with AAV receiving rituximab. trimethoprim–
sulfamethoxazole prophylaxis reduced the risk, while 
especially bronchiectasis and endobronchial involvement 
are risk factors for severe respiratory infections.
IntrOduCtIOn
Antineutrophil cytoplasm antibody (ANCA)-asso-
ciated vasculitis (AAV) encompasses three entities, 
namely granulomatosis with polyangiitis (GPA, 
previously Wegener’s granulomatosis), microscopic 
polyangiitis (MPA) and eosinophilic granulomatosis 
with polyangiitis (EGPA, previously Churg-Strauss 
Syndrome). The availability of ANCA facilitates 
diagnosis and treatment strategies, and has led to 
a better prognosis over recent decades.1 Neverthe-
less, comorbidities attributable to the persistence 
of the disease or side effects of treatment remain a 
challenge. Forty-eight per cent of deaths occurring 
during the first year are caused by infections and 
remain a major cause of mortality thereafter.2 Infec-
tious complications have been studied especially in 
cyclophosphamide-treated patients. Several risk 
factors have been identified, including treatment 
intensity (cumulative steroid and cyclophospha-
mide dose), reduced creatinine clearance (estimated 
glomerular filtration rate (eGFR) of ≤30 mL/min) 
or dialysis dependency, older age and pulmonary 
involvement.3 Rituximab showed similar effi-
cacy compared with a cyclophosphamide-based 
treatment in the induction of remission in two 
randomised controlled trials. However, rituximab 
did not show a reduced rate of severe infections 
compared with cyclophosphamide.4 5 Patients 
recruited into trials may have a lower adverse 
event rate due to rigorous monitoring and selec-
tion of patients according to exclusion criteria,6 
and the rate of side effects might be even higher in 
routine practice. Several observational studies have 
reported severe/life-threatening infectious compli-
cations following rituximab, including cases with 
Pneumocystis jirovecii, Pseudomonas aeruginosa, 
pulmonary aspergillosis and progressive multifocal 
leukoencephalopathy.7–9 While P. jirovecii prophy-
laxis is widely accepted in patients receiving cyclo-
phosphamide (CYC), no such recommendations 
exist for patients receiving rituximab.
This study investigated the frequency of severe/
life-threatening infections in 192 patients with 
AAV treated with rituximab. It also aimed to iden-
tify risk factors for severe infection in this patient 
population.
MethOds
study population
This study included patients with AAV older 
than 18 years who were referred for rituximab 
to two tertiary care specialist centres, Adden-
brooke’s Hospital (Cambridge, UK) and the 
Medical University Innsbruck (Innsbruck, Austria), 
between 2004 and 2014. Diagnosis of AAV was 
established according to the European Medicines 
Agency (EMA) algorithm.10 Follow-up of patients 
began at the time of rituximab administration 
and ended on the date of death, the date patients 
were lost to follow-up, 2 years after first rituximab 
to cite: Kronbichler A, 
Kerschbaum J, 
Gopaluni S, et al. 
Ann Rheum Dis Epub ahead 
of print: [please include day 
Month Year]. doi:10.1136/
annrheumdis-2017-212861
handling editor Josef S 
Smolen
 ► Additional material is 
published online only. to view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
annrheumdis- 2017- 212861).
1Vasculitis and Lupus Clinic, 
Addenbrooke’s Hospital, 
Cambridge, UK
2department of Internal 
Medicine IV (nephrology and 
Hypertension), Anichstraße, 
Innsbruck, Austria
3renal Medicine and Vasculitis 
Clinic, San Carlo Borromeo 
Hospital, Milan, Italy
4department of Medicine, 
University of Cambridge, 
Cambridge, UK
Correspondence to
dr Andreas Kronbichler, 
Vasculitis and Lupus Clinic, 
Addenbrooke’s Hospital, 
Cambridge CB2 0QQ, UK;  
 andreas. kronbichler@ i- med. 
ac. at
parts of this work were 
presented during the 52nd ErA-
EdtA Congress 2015 (London, 
UK) and during the ASn Kidney 
Week 2016 (Chicago, USA).
received 16 december 2017
Accepted 11 June 2018
© Author(s) (or their 
employer(s)) 2018. re-use 
permitted under CC BY-nC. no 
commercial re-use. See rights 
and permissions. published 
by BMJ.
 o
n
 28 August 2018 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2017-212861 on 27 June 2018. Downloaded from
 
2 Kronbichler A, et al. Ann Rheum Dis 2018;0:1–8. doi:10.1136/annrheumdis-2017-212861
Clinical and epidemiological research
administration or on 1 January 2015, whichever occurred first. 
This study was conducted in accordance with the ethical prin-
ciples stated in the Declaration of Helsinki. The Institutional 
Review Board of both university hospitals approved the use of 
anonymised patient data for research purposes.
Clinical data
The following data were obtained from the respective electronic 
medical records of the patients: demography (age, gender), 
diagnosis, date of diagnosis, time to rituximab, ANCA sero-
type, disease phenotype, organ involvement, prior immunosup-
pressive therapies, cumulative cyclophosphamide exposure (in 
grams), immunosuppression during the year before rituximab, 
concomitant treatment, laboratory values (serum creatinine, 
C reactive protein (CRP), erythrocyte sedimentation rate (ESR), 
neutrophils, white blood count (WBC), lymphocytes, CD3/
CD4/CD8/CD19/CD56 counts, immunoglobulins), indication 
for the use of rituximab (see  online supplementary appendix), 
comorbidities (including chronic obstructive pulmonary disease, 
diabetes mellitus, hypertension, chronic heart failure), smoking 
history, antibiotic prophylaxis (trimethoprim–sulfamethoxazole 
or others) and the occurrence of severe/life-threatening infec-
tions (grade ≥3), as classified by the Common Terminology 
Criteria for Adverse Events (CTCAE) V.4.0 (see online supple-
mentary appendix).11 Hypogammaglobulinaemia was defined as 
a IgG level of below 7 g/L. Patients with incomplete or missing 
medical records were excluded from further analyses. The cumu-
lative doses of rituximab during follow-up were determined.
statistical analysis
Categorical variables were compared using the χ2 test (or Fish-
er’s exact test, when appropriate), and metric variables were 
compared using the Mann-Whitney U test. Metric variables are 
shown as median (and minimum to maximum), and nominal 
variables are shown as per cent (%). Both univariate and multi-
variate Cox regression analyses were performed to determine 
significant risk factors for severe/life-threatening and respiratory 
infections. The occurrence of at least one episode of severe/
life-threatening infection during the follow-up period of 24 
months was the outcome of interest. Kaplan-Meier plots and 
log-rank test were performed to assess univariate associations. 
All variables showing significant association with the dependent 
variable in the univariate Cox regression analysis were entered 
into a multivariate Cox regression model. A backward selection 
procedure was then used (with p values greater than 0.100 as 
the removal criterion, using Wald’s test). Neutrophils correlated 
with WBC, CRP and ESR and sinusitis correlated with ear, nose 
and throat (ENT) involvement, thus only neutrophils at base-
line and sinusitis were included in multivariate analysis. Results 
are expressed as HRs with 95% CIs. All statistical analyses were 
performed with SPSS Statistics V.21.0 (IBM).
results
Patient characteristics
The total number of patients included in the analysis was 192 
(134 with GPA, 28 with MPA and 30 with EGPA). Mean dura-
tion of initial diagnosis to initiation of rituximab was 4.33 years. 
Patients were followed for a mean time of 22.67 months from 
the time of rituximab initiation (mean rituximab dose 4.75 g). 
Forty-nine patients presented with 95 infectious complications 
classified as CTCAE V.4.0 ≥3. In detail, 71 episodes were 
CTCAE V.4.0 grade 3, 23 as grade 4 and 1 as grade 5 (multi-
organ failure as a consequence of sepsis related to an urinary 
tract infection). The overall event rate was 26.06 per 100 
person-years. Twenty-five per cent of the observed infections 
occurred during the first 4 months of follow-up, while 50% and 
80% were observed after 12 and 18 months, respectively. Anti-
biotic prophylaxis with trimethoprim–sulfamethoxazole was 
administered in 73 out of 192 (38.02%). During the follow-up 
period, seven fatalities were recorded. Baseline characteristics of 
patients with severe infections and those without are depicted 
in table 1.
Infections
Respiratory tract infection was the most common infectious 
complication (n=63), followed by urinary tract (n=12), gastro-
intestinal tract (n=8), mastoiditis/otitis externa (n=4), skin 
(n=3), sepsis/septicaemia with unidentified site of infection 
(n=1), catheter-associated exit site infections (n=1), orbital 
mass infection (n=1), lacrimal gland abscess (n=1) and eye 
(n=1) (online supplementary table S1). Moreover, in cases with 
a positive microbial result, opportunistic pathogens were seen, 
including P. aeruginosa (n=4), Staphylococcus aureus including 
methicillin-resistant strains (n=4), Escherichia coli (n=3), 
Clostridium difficile (n=2), P. jirovecii (n=1), Legionella pneu-
mophila (n=1) and invasive aspergillosis (n=1). In addition, 
one case of Campylobacter jejuni gastroenteritis was observed 
(online supplementary table S1 and online supplementary table 
S2).
rituximab treatment and risk of infections
To identify specific risk factors associated with the development 
of infectious complications, univariate analysis was performed. 
Older patients (HR 1.02, 95% CI 1.00 to 1.04), patients with 
endobronchial involvement (HR 2.44, 95% CI 1.38 to 4.32) 
and severe bronchiectasis (HR 4.79, 95% CI 1.47 to 15.59) 
were at increased risk for severe infections. Patients presenting 
with sinusitis (HR 0.48, 95% CI 0.27 to 0.84) or in general 
ENT involvement (HR 0.46, 95% CI 0.26 to 0.82) had fewer 
severe infections. While there was no correlation with serum 
creatinine, higher eGFR (HR 0.99, 95% CI 0.98 to 1.00) 
emerged as a protective factor. Higher ESR (HR 1.11, 95% CI 
1.03 to 1.20), WBC (HR 1.06, 95% CI 1.01 to 1.10), higher 
steroid doses (HR 1.02, 95% CI 1.01 to 1.04) and an IgG decline 
≥30% (HR 1.88, 95% CI 1.04 to 3.39) at baseline were predic-
tors of severe infections. Concomitant comorbidities, such as 
chronic obstructive pulmonary disease (COPD, HR 16.07, 
95% CI 4.41 to 58.49), diabetes (HR 2.35, 95% CI 1.14 to 4.85) 
and reduced left ventricular ejection fraction/previous myocar-
dial infarction (HR 2.21, 95% CI 1.07 to 4.56) emerged as risk 
factors. Treatment with alemtuzumab (ALM) ever before ritux-
imab was associated with an increased risk (HR 2.49, 95% CI 
1.05 to 5.91). Antibiotic prophylaxis to prevent P. jirovecii infec-
tions with trimethoprim–sulfamethoxazole reduced the risk of 
severe infections (HR 0.45, 95% CI 0.23 to 0.88). A multivar-
iate logistic regression analysis revealed that the use of trimetho-
prim–sulfamethoxazole as prophylactic antibiotic measure had 
an impact on reduction of severe infections (HR 0.30, 95% CI 
0.13 to 0.69). Moreover, the use of trimethoprim–sulfamethox-
azole significantly reduced the time to first significant infection 
(p=0.016) (table 2 and figure 1). Moreover, older age (HR 1.03, 
95% CI 1.01 to 1.05), endobronchial involvement (HR 2.21, 
95% CI 1.15 to 4.26), COPD (HR 6.30, 95% CI 1.08 to 36.75) 
and ALM treatment before rituximab (HR 3.97, 95% CI 1.50 
to 10.54) emerged as independent risk factors to develop severe 
infections following rituximab (table 2).
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table 1 Baseline characteristics of patients having severe infections versus those without severe infections
no severe infection (n=143) severe infection (n=49) P values
Demographics
  Age (years) 56 (16–85) 60 (22–82) 0.023
  Gender (male, %) 45 41 0.573
  Type of vasculitis (%) 0.407
  GPA 71 65
  MPA 13 20
  EGPA 16 14
Symptoms (%)
  B-symptoms (night sweat, fever, unintentional weight loss) 21 14 0.353
  Neuropathy 27 24 0.774
  Sinusitis 72 53 0.015
  Deafness/mastoiditis/otitis media 31 22 0.266
  Arthralgia 45 33 0.117
Organ involvement (%)
  CNS 7 7 1
  Subglottic/tracheal stenosis 12 14 0.661
  Skin 18 14 0.533
  Kidney 44 51 0.398
  Eye 29 17 0.112
  Others 7 8 1
  ENT 79 61 0.014
  Lung 54 65 0.162
Imaging findings (%)
  Pulmonary cavities 24 26 0.75
  Endobronchial 20 41 0.004
  Severe bronchiectasis 1 8 0.054
Disease activity measures
  BVAS 6 (0–28) 6 (0–18) 0.602
  DEI 6 (2–12) 6 (2–10) 0.848
Laboratory values
  Creatinine (µmol/L) 86 (45–1451) 98 (49–879) 0.027
  eGFR (MDRD/Modification of Diet in Renal Disease equation) mL/min/1.73 m2 75 (3–163) 60 (5–155) 0.002
  CRP (0–6 mg/L) 5.0 (0.7–215.0) 14.0 (1.0–215.0) 0.001
  ESR (5–15 in the 1st hour) 16 (2–116) 22 (1–109) 0.006
  Neutrophils (2–8×109/L) 7.1 (2.0–18.6) 8.3 (2.4–21.4) 0.025
  WBC (4–11×109/L) 9.4 (3.6–42.0) 10.7 (3.3–24.4) 0.006
  Lymphocytes (1–4.5×109/L) 1.0 (0.1–3.7) 1.0 (0.4–4.5) 0.145
  CD19 (0.1–0.5) 0.04 (0.00–0.80) 0.03 (0.00–0.77) 0.781
  CD3 (0.7–2.1) 0.82 (0.05–7.20) 0.70 (0.21–3.32) 0.246
  CD4 (0.3–1.4) 0.48 (0.03–1.98) 0.38 (0.11–2.80) 0.303
  CD8 (0.2–0.9) 0.29 (0.02–1.93) 0.20 (0.07–0.95) 0.414
  CD56 (0.12–0.88) 0.11 (0.00–0.70) 0.15 (0.00–0.80) 0.09
  IgG (6–13 g/L) 9.0 (2.8–22.6) 8.8 (3.0–18.9) 0.823
  IgG decline ≥30% (%) 20 35 0.041
  Hypogammaglobulinaemia (%) 13 16 0.593
  IgM (0.4–2.2 g/L) 0.7 (0.3–2.6) 0.7 (0.3–2.0) 0.398
  IgA (0.8–3.7 g/L) 1.8 (0.4–5.3) 2.1 (0.5–4.3) 0.715
  ANCA-positive (%) 73 76 0.703
Comorbidities (%)
  COPD 1 6 0.053
  Diabetes 6 18 0.021
  Hypertension 37 33 0.557
  Myocardial infarction/reduced LVEF 8 18 0.036
Indication (%)
  Minor relapse 41 29 0.114
  Major relapse 27 39 0.13
Continued
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risk for lower respiratory tract infections after rituximab
Since respiratory tract infections were the leading cause of 
infectious complications (n=63), we aimed to identify factors 
predicting the risk. Nine patients underwent bronchoscopy and 
most of them had at least two respiratory tract infections (7/9). 
Patients with preserved eGFR (HR 0.99, 95% CI 0.98 to 1.00), 
presenting with sinusitis (HR 0.47, 95% CI 0.23 to 0.98) and 
ENT involvement (HR 0.43, 95% CI 0.20 to 0.87) as well as 
receiving rituximab for refractory disease (HR 0.35, 95% CI 
0.12 to 0.99), had a lower likelihood to develop severe pulmo-
nary infections. In contrast, lung involvement (HR 2.53, 95% CI 
1.08 to 5.93) and in particular endobronchial involvement (HR 
4.30, 95% CI 2.06 to 8.94) and severe bronchiectasis (HR 7.48, 
95% CI 2.22 to 25.16) emerged as risk factors. Higher CRP 
(HR 1.01, 95% CI 1.00 to 1.01), ESR (HR 1.02, 95% CI 1.00 to 
1.03), neutrophils (HR 1.15, 95% CI 1.15) and WBC (HR 1.07, 
95% CI 1.01 to 1.12) at baseline were associated with severe 
pulmonary infections. Moreover, those with concomitant COPD 
(HR 19.75, 95% CI 5.23 to 74.63), major relapse as indication 
(HR 2.65, 95% CI 1.28 to 5.49) and higher steroid doses (HR 
1.02, 95% CI 1.00 to 1.04) had more pulmonary infections. 
Multivariate analysis retained endobronchial involvement (HR 
4.30, 95% CI 2.06 to 8.94), severe bronchiectasis (HR 7.48, 
95% CI 2.22 to 25.16), neutrophil count at baseline (HR 1.19, 
95% CI 1.06 to 1.33) and major relapse (HR 2.65, 95% CI 1.28 
to 5.49) as independent risk factors, while rituximab use in 
the setting of refractory disease was negatively associated with 
severe pulmonary infections (HR 0.35, 95% CI 0.12 to 0.99) 
(online supplementary table S3).
Prescription pattern and side effects of trimethoprim–
sulfamethoxazole
The dose of trimethoprim–sulfamethoxazole used as a prophy-
laxis was not consistent. Most patients received 480 mg on 
alternate days (38.36%), followed by 960 mg on alternate days 
(21.92%) and 960 mg twice daily (12.33%, further details 
see online supplementary table S4). Among differences in the 
prescription pattern, a diagnosis of GPA, ENT involvement 
including sinusitis and deafness, mastoiditis and otitis media 
were associated with a more frequent prescription. Lower CD4 
T-cell count as well as cyclophosphamide in the year before and 
a higher concomitant steroid use led to trimethoprim–sulfame-
thoxazole prescription (online supplementary table S5). Next, 
we assessed side effects of trimethoprim–sulfamethoxazole 
focusing on recently reported adverse events in rheumatolog-
ical indications.12 Trimethoprim–sulfamethoxazole was stopped 
in five patients due to haematopoietic complications in three 
(lymphopenia, pancytopenia, neutropenia), sore mouth in one 
and abnormal liver function test in the remainder. In general, 
trimethoprim–sulfamethoxazole prophylaxis was maintained for 
14.67 months.
dIsCussIOn
Comorbidities, either attributable to active disease or immuno-
suppression, remain a major issue in the management of AAV. 
An analysis of the early EUVAS trials revealed that infections 
contributed to the majority (28/59, 48%) of deaths within the 
first year of trial inclusion, whereas it is among the three leading 
causes thereafter (15/74, 20%). A direct effect of induction treat-
ment was proposed to be causative of severe infections within 
the first year.2 A recent study analysing the Chapel Hill cohort 
highlighted that infections were responsible for a high propor-
tion of deaths within the first year (4/31, 13%), while active 
disease (29%) was the leading cause in a large cohort comprising 
421 patients with a follow-up of at least 1 year.13 Differences in 
the treatment modalities may have accounted for the differences 
leading to fatal infections in diverse cohorts. The methylprednis-
olone versus plasma exchange (MEPEX) trial (one of the early 
European Vasculitis Society (EUVAS) trials) randomised patients 
no severe infection (n=143) severe infection (n=49) P values
  Maintenance 78 82 0.622
  Refractory disease 31 27 0.516
  Steroid sparing 17 22 0.375
  1st line 5 10 0.187
Premedication (last 12 months)
  CYC (g) 0 (0–45) 0 (0–22) 0.632
  MMF (g) 0 (0–1080) 15 (0–1080) 0.798
  AZA (g) 0 (0–81) 0 (0–72) 0.036
  MTX (mg) 0 (0–1286) 0 (0–1286) 0.739
  IVIG (ever) (%) 4 12 0.128
  Anti-TNF (ever) (%) 3 5 0.65
  PLEX (ever) (%) 9 7 1
  ALM (ever) (%) 5 14 0.079
Medication used concurrently with RTX 
  Steroids (mg) 15 (0–60) 15 (5–60) 0.087
  Trimethoprim–sulfamethoxazole (%) 43 22 0.009
  Other antibiotic prophylaxis (%) 9 16 0.172
Metric variables are shown as median and (minimum–maximum), nominal variables are shown as %. Statistics tests are χ quadrate test/Fisher’s exact test and Mann-Whitney U 
test where appropriate. The respective reference ranges, if applicable, are given in parentheses. P values indicating significant changes are highlighted in bold font. 
ALM, alemtuzumab; ANCA, antineutrophil cytoplasm antibody; AZA, azathioprine; BVAS, Birmingham Vasculitis Activity Score; CD, cluster of differentiation; CNS, central nervous 
system; COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; CYC, cyclophosphamide; DEI, Disease Extent Index; eGFR, estimated glomerular filtration rate; 
EGPA, eosinophilic granulomatosis with polyangiitis; ENT, ear, nose and throat; ESR, erythrocyte sedimentation rate; GPA, granulomatosis with polyangiitis; IVIG, intravenous 
immunoglobulins; LVEF, left ventricular ejection fraction; MMF, mycophenolate mofetil; MPA, microscopic polyangiitis; MTX, methotrexate; PLEX, plasma exchange; RTX, 
rituximab; TNF, tumour necrosis factor; WBC, white blood count.
table 1 Continued 
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table 2 Univariate and multivariate analysis of risk factors for severe or life-threatening infection following rituximab treatment during 24 
months of follow-up
univariate analysis Multivariate analysis
hr 95 % CI P values hr 95 % CI P values
Demographics
  Age (years) 1.02 1.00 to 1.04 0.031 1.03 1.01 to 1.05 0.012
  Gender (male) 0.88 0.50 to 1.55 0.647
Type of vasculitis
  GPA Reference – – 
  MPA 1.59 0.78 to 3.23 0.203
  EGPA 0.95 0.42 to 2.15 0.899
Symptoms/manifestations
  B-symptoms (night sweat, fever, unintentional weight loss) 0.67 0.28 to 1.58 0.355
  Neuropathy 0.89 0.46 to 1.70 0.72
  Sinusitis 0.48 0.27 to 0.84 0.01
  Deafness/mastoiditis/otitis media 0.69 0.35 to 1.35 0.275
  Arthralgia 0.63 0.35 to 1.14 0.127
Organ involvement
  CNS 1.12 0.35 to 3.63 0.85
  Subglottic/tracheal stenosis 1.14 0.51 to 2.54 0.746
  Skin 0.74 0.33 to 1.64 0.45
  Kidney 1.27 0.72 to 2.21 0.411
  Eye 0.52 0.23 to 1.17 0.113
  Others 0.82 0.26 to 2.65 0.745
  ENT 0.46 0.26 to 0.82 0.008
  Lung 1.57 0.87 to 2.82 0.136
Imaging findings
  Pulmonary cavities 1.11 0.56 to 2.21 0.765
  Endobronchial 2.44 1.38 to 4.32 0.002 2.21 1.14 to 4.26 0.018
  Severe bronchiectasis 4.79 1.47 to 15.59 0.009
Disease activity measures 
  BVAS 1.01 0.95 to 1.07 0.811
  DEI 0.98 0.84 to 1.15 0.840 
Laboratory values 
  Creatinine 1 1.00 to 1.00 0.141
  eGFR (MDRD equation) mL/min/1.73 m2 0.99 0.98 to 1.00 0.011
  CRP 1.01 1.00 to 1.01 0.061
  ESR 1.01 1.00 to 1.02 0.014
  Neutrophils 1.11 1.03 to 1.20 0.005
  WBC 1.06 1.01 to 1.10 0.013
  Lymphocytes 0.73 0.48 to 1.11 0.142
  CD19 1.17 0.11 to 12.51 0.896
  CD3 0.75 0.45 to 1.25 0.27
  CD4 0.74 0.34 to 1.61 0.44
  CD8 0.58 0.16 to 2.09 0.407
  CD56 2.75 0.34 to 22.10 0.341
  IgG 1.02 0.93 to 1.12 0.663
  IgG decline ≥30 % 1.88 1.04 to 3.39 0.036
  Hypogammaglobulinaemia 1.22 0.54 to 2.74 0.633
  IgM 0.72 0.38 to 1.35 0.304
  IgA 1.11 0.80 to 1.54 0.535
  ANCA positive 1.11 0.58 to 2.14 0.744
Comorbidities
  COPD 16.07 4.41 to 58.49 <0.001 6.3 1.08 to 36.75 0.041
  Diabetes 2.35 1.14 to 4.85 0.021
  Hypertension 0.79 0.44 to 1.44 0.445
  Myocardial infarction/reduced LVEF 2.21 1.07 to 4.56 0.032
Indication
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either to plasma exchange or high-dose methylprednisolone 
alongside standard induction therapy reported 19 deaths (out of 
137 patients) related to infections within the first year.14
Little is known about infections in patients with AAV treated 
with rituximab. In the first 6 months, the rate of severe infections 
(defined as grade ≥3 CTCAE V.3.0 event) was 7% in the group 
of patients receiving either rituximab or standard of care in the 
RAVE trial.4 Over 18 months, 12% in the rituximab and 11% 
of participants in the standard of care group had at least one 
episode of grade ≥3 infections.6 In the RITUXVAS trial, a higher 
occurrence of severe infectious complications was observed in 
both treatment arms. While the rate of severe infections was 18% 
in both arms, the number of patients presenting with non-severe 
infections was higher (18% vs 9%) in the rituximab group.5 In 
general, patients with vasculitis may carry an increased risk to 
develop severe infections following rituximab administration. 
In patients with rheumatoid arthritis (RA), long-term follow-up 
of a global clinical trial programme revealed a serious infection 
event rate of 3.76 per 100 person-years. In contrast to our find-
ings, opportunistic infections remained rare during follow-up 
with an event rate of 0.05 events per 100 patient-years in the 
RA cohort.15
The current European League Against Rheumatism/European 
Renal Association - European Dialysis and Transplant Associa-
tion (EULAR/ERA-EDTA) recommendations for the manage-
ment of AAV encourage P. jirovecii prophylaxis in patients 
receiving cyclophosphamide.16 However, no concrete recom-
mendation concerning rituximab is given. In the updated EMA 
label, prophylaxis is recommended during and following ritux-
imab, as appropriate.17 In this study, the frequency of P. jirovecii 
infection was low (n=1). This frequency is in line with a study 
reporting one case of P. jirovecii in patients receiving mainly 
cyclophosphamide as induction treatment.13 Currently, it is 
uncertain if patients with AAV receiving rituximab benefit from 
P. jirovecii prophylaxis since the reported frequency of severe 
adverse events attributable to trimethoprim–sulfamethoxazole is 
high in patients with systemic autoimmune diseases, with some 
fatalities.12 18 A randomised controlled trial investigating the 
role of trimethoprim–sulfamethoxazole in therapeutic dosage 
(960 mg twice a day for 2 years) found a reduction in respiratory 
univariate analysis Multivariate analysis
hr 95 % CI P values hr 95 % CI P values
  Minor relapse 0.6 0.32 to 1.11 0.102
  Major relapse 1.63 0.92 to 2.90 0.097
  Maintenance 1.15 0.56 to 2.37 0.708
  Refractory disease 0.8 0.42 to 1.51 0.491
  Steroid sparing 1.37 0.70 to 2.68 0.36
  1st line 1.95 0.77 to 4.91 0.159
Premedication (last 12 months)
  CYC (g) 0.97 0.90 to 1.04 0.389
  MMF (g) 1 1.00 to 1.00 0.273
  AZA (g) 0.97 0.95 to 1.00 0.066
  MTX (mg) 1 1.00 to 1.00 0.979
  IVIG (ever) 2.4 0.94 to 6.12 0.067
  Anti-TNF (ever) 1.41 0.34 to 5.84 0.636
  PLEX (ever) 0.75 0.23 to 2.42 0.629
  ALM (ever) 2.49 1.05 to 5.91 0.039 3.97 1.50 to 10.54 0.006
Medication used concurrently with RTX
  Steroids (mg) 1.02 1.01 to 1.04 0.006
  Trimethoprim–sulfamethoxazole 0.45 0.23 to 0.88 0.02 0.3 0.13 to 0.69 0.005
  Other antibiotic prophylaxis 1.63 0.76 to 3.47 0.209
Demographics of the respective patients, the form of ANCA-associated vasculitis, symptoms, laboratory values, comorbidities, indication for rituximab use, the premedication and 
the concomitant therapy are given. P values indicating significant changes are highlighted in bold font.
ALM, alemtuzumab; ANCA, antineutrophil cytoplasm antibody; AZA, azathioprine; BVAS, Birmingham Vasculitis Activity Score; CD, cluster of differentiation; CNS, central nervous 
system; COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; CYC, cyclophosphamide; DEI, Disease Extent Index; eGFR, estimated glomerular filtration rate; 
EGPA, eosinophilic granulomatosis with polyangiitis; ENT, ear, nose and throat; ESR, erythrocyte sedimentation rate; GPA, granulomatosis with polyangiitis; IVIG, intravenous 
immunoglobulins; LVEF, left ventricular ejection fraction; MMF, mycophenolate mofetil; MPA, microscopic polyangiitis; MTX, methotrexate; PLEX, plasma exchange; RTX, 
rituximab; TNF, tumour necrosis factor; WBC, white blood count.
table 2 Continued 
Figure 1 Kaplan-Meier curve of patients presenting with severe 
infections and either receiving trimethoprim–sulfamethoxazole or 
prophylaxis or not.
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tract infections and a trend towards fewer non-respiratory 
tract infections (p=0.05) compared with placebo.19 This is in 
line with our study confirming a protective effect of prophy-
lactic trimethoprim–sulfamethoxazole use on the risk to develop 
severe infections. Thus, it may be appropriate to conclude that 
trimethoprim–sulfamethoxazole may reduce P. jirovecii pneu-
monia and also reduces overall infective risk and prophylaxis 
should be initiated in patients with AAV receiving rituximab. In 
our cohort, patients tolerating trimethoprim–sulfamethoxazole 
remained on prophylaxis during the 2-year period (mean 14.67 
months). Five patients stopped trimethoprim–sulfamethoxazole 
due to adverse events.
The reported occurrence of severe infections in observa-
tional studies of AAV varies (frequency 20%–60%)3 influenced 
by follow-up times, prophylactic measures and the impact of 
different criteria for infections. In our study, 26.06% patients 
presented with at least one severe infection. The observed 
frequency is higher compared with both Rituximab versus 
Cyclophosphamide for ANCA-Associated Vasculitis (RAVE) 
and Rituximab versus Cyclophosphamide in ANCA-Associated 
Renal Vasculitis (RITUXVAS) trials. This may be explained by 
the scheduled rigorous study visits, allowing for early detec-
tion of infection and prescription of antimicrobials, or the 
selection of a lower risk cohort for the clinical trials. However, 
the frequency of observed severe infections is similar to other 
observational studies reported to date.7 8 20 Older age was an 
independent risk factor for infections in the pre-rituximab era.3 
We observed an association between age and severe infections 
in our cohort. Patients with lung involvement and concomi-
tant COPD may be particularly vulnerable to severe infections. 
Endobronchial involvement and COPD were risk factors for 
infections and endobronchial involvement alongside severe 
bronchiectasis predictors of severe pulmonary infections. In 
patients with AAV on immunosuppressive treatment, most 
severe infections are located in the respiratory tract.13 21 22 In 
rituximab-treated patients, 20 out of 30 infectious complica-
tions were restricted to the upper and lower respiratory tract 
during a follow-up period of 230.4 patient-years.8 Respiratory 
tract infections were the leading cause of severe infections in 
our cohort as well.
Compared with a matched background population, patients 
with AAV are at an increased risk of severe infections, including 
non-specific (HR 4.55), Gram-negative (HR 3.49) and S. 
aureus septicaemia (HR 3.40), pneumonia (HR 3.27), acute 
upper respiratory tract infections (HR 8.88), C. difficile infec-
tion (HR 5.35) and skin infections (HR 5.35).23 Interestingly, 
no difference related to infectious complications was observed 
when an early cohort was compared with a recent cohort.23 
Another study corroborated an impact of S. aureus in patients 
with AAV, being the most prevalent causative organism (34% of 
249 positive cultures). Among 85 positive cultures, 18 (21%) 
of S. aureus isolates were grown despite trimethoprim–sulfame-
thoxazole prophylaxis. Moreover, 14% of infections caused by 
S. aureus were severe.13 In contrast, our study found a broad 
spectrum of opportunistic pathogens and P. aeruginosa as well 
as S. aureus (four severe infections, each) were the leading caus-
ative organism, followed by E. coli (three severe infections). The 
spectrum of isolates is in line with a recent study reporting the 
efficacy and safety profile of rituximab in induction and main-
tenance of remission. Out of 12 severe infections, four led to 
fatality in four subjects with either coma (meningitis) or respi-
ratory failure (pneumonitis with detection of P. aeruginosa or P. 
jirovecii).7 Both S. aureus and Gram-negative bacteria may have 
a direct impact on disease onset or relapse,24 which is a potential 
explanation for the high number of infections caused by these 
pathogens.
Most infections occur within the first months of treatment. 
McGregor et al showed the highest risk of infections during the 
first 3 months of follow-up and in general severe infections within 
the first 12 months were associated with death (19% vs 4%).13 
A recent registry analysis highlighted that a high proportion of 
severe infections occurred during the first 6 months of follow-up 
(38.4%).23 In contrast, severe infections occurred during the 
whole observational period in our cohort of rituximab-treated 
patients. In retrospective studies, hypogammaglobulinaemia was 
a frequently observed complication of rituximab with the need 
of IgG replacement due to recurrent infections in 4.2% of the 
patients.25 Univariate analysis revealed an association between 
IgG decline of at least 30% from baseline in patients with severe 
infections. This may indicate that this subgroup of patients with 
a drop in IgG levels may be specifically prone towards infections.
In conclusion, we found severe infections occurring in 
approximately one quarter of patients in a 2-year observation 
period after rituximab therapy for AAV. There was a reduc-
tion of severe infections when trimethoprim–sulfamethoxazole 
prophylaxis was used. Respiratory tract infections were the 
leading cause of severe infections. We found an association of 
endobronchial involvement, bronchiectasis and rituximab use 
for major relapses with severe respiratory tract infections. While 
these results require confirmation, they support routine use of 
trimethoprim–sulfamethoxazole in rituximab-treated patients.
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